No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients
Claire Bridel(University of Geneva), Charlotte E. Teunissen(Amsterdam Neuroscience), Cyra E Leurs(Vrije Universiteit Amsterdam), Menno M. Schoonheim(Amsterdam Neuroscience), A. J. C. Eijlers(Amsterdam Neuroscience), Joep Killestein(Amsterdam UMC Location Vrije Universiteit Amsterdam), Wessel N. van Wieringen(University Medical Center), Marleen J.A. Koel‐Simmelink(Amsterdam UMC Location Vrije Universiteit Amsterdam)
Cited by 7
Related Papers
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
|Alzheimer s & Dementia|2024|2.3k
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology
|JAMA Neurology|2019|750
Loss of ‘Small-World’ Networks in Alzheimer's Disease: Graph Analysis of fMRI Resting-State Functional Connectivity
|PLoS ONE|2010|621
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
|Alzheimer s & Dementia|2022|589
A Practical Guide to Immunoassay Method Validation
|Frontiers in Neurology|2015|541